A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.

ABSTRACT:

Purpose

The Phase III POTENT trial demonstrated the efficacy of adding S-1 to adjuvant endocrine therapy for estrogen receptor-positive, HER2-negative early breast cancer. We investigated the efficacy of S-1 across different recurrence risk subgroups.

Methods

This was a post-hoc exploratory analysis of the POTENT trial. Patients in the endocrine-therapy-only arm were divided into three groups based on composite risk values calculated from multiple prognostic factors. The effects of S-1 were estimated using the Cox model in each risk group. The treatment effects of S-1 in patients meeting the eligibility criteria of the monarchE trial were also estimated.

Results

A total of 1,897 patients were divided into three groups: group 1 (≤ lower quartile of the composite values

SUBMITTER: Takada M 

PROVIDER: S-EPMC10564670 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature